Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24192519 | 0.91 | USP30 (0.36) | USP30BACE1BACE2PRMT5WDR77 | |
| SCHEMBL25969622 | 0.89 | USP30 (0.39) | USP30BACE1BACE2DGAT1PRMT5 | |
| SCHEMBL25969654 | 0.87 | USP30 (0.37) | USP30BACE1BACE2DGAT1PRMT5 | |
| SCHEMBL25969641 | 0.81 | USP30 (0.39) | USP30BACE1BACE2DGAT1PRMT5 | |
| SCHEMBL25969661 | 0.80 | USP30 (0.37) | USP30BACE1BACE2DGAT1PRMT5 | |
| SCHEMBL18391604 | 0.74 | AAK1 (0.49) | USP30BACE1BACE2DGAT1PRMT5 | |
| SCHEMBL15412342 | 0.69 | USP30 (0.40) | USP30BACE1BACE2DGAT1PRMT5 | |
| SCHEMBL25345280 | 0.68 | PDK2 (0.34) | AAK1 | |
| SCHEMBL1529947 | 0.68 | LPL (0.40) | FFAR1 | |
| SCHEMBL25874089 | 0.68 | DUT (0.41) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | USP30 4382/4885BACE1 2544/4885BACE2 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.